VIDEO WITH SASKIA HOFSTEDE
About a new treatment option for adult patients with BRAFV600E-mutant metastatic colorectal cancer.
The EC approval of BRAFTOVI® (encorafenib) was based on the results from the Phase 3 BEACON CRC trial
(Ref: Kopetz S, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381:1632–43)